- In January 2025, Thermo Fisher Scientific announced the launch of its next-generation serum testing platform, designed to enhance the accuracy and efficiency of serum-based diagnostics. The new platform integrates advanced AI algorithms for real-time analysis of biomarkers, providing faster and more reliable results for managing chronic diseases such as diabetes and cardiovascular conditions. The platform also offers customizable testing options for personalized medicine, supporting more tailored treatment regimens for patients
- In December 2024, Abbott Laboratories unveiled a new line of serum-based diagnostic assays, focusing on the early detection of multiple chronic conditions, including liver disease and cardiovascular disorders. These tests are designed to provide high sensitivity and specificity, ensuring early diagnosis and better treatment outcomes. Abbott’s innovative solutions are expected to drive significant growth in the global serum market, especially in regions with rising healthcare demands
- In November 2024, Siemens Healthineers introduced its updated serum biomarker testing system, which improves the speed and accuracy of serum analysis for oncology and infectious diseases. The system incorporates a fully automated workflow, reducing human error and enhancing laboratory productivity. This development is poised to revolutionize serum testing in clinical laboratories and hospitals, ensuring quicker diagnostic decisions for patients globally
- In September 2024, Roche Diagnostics launched a new serum-based test for cardiovascular health monitoring. The test measures multiple biomarkers simultaneously, allowing healthcare providers to better manage heart disease and related conditions. This advancement underscores the growing importance of serum diagnostics in the early detection and management of chronic conditions, further fuelling the expansion of the serum market
